Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Br J Cancer. 2011 Mar 29;104(7):1067-70. doi: 10.1038/bjc.2011.76. Epub 2011 Mar 8.

Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours.

Author information

  • 1University Department of Medical Oncology, Cancer and Haematology Centre, Churchill Hospital, Headington OX3 7LJ, UK.

Abstract

BACKGROUND:

This study sought to determine the safety of single agent capecitabine, a pro-drug of 5FU, in patients with metastatic non-pancreatic neuroendocrine tumours (NETs).

METHODS:

Multicentre phase II, first-line study design. Oral capecitabine was administered on days 1-14 of 3-week cycles.

RESULTS:

Treatment was safe and well tolerated. Common toxicities were diarrhoea and fatigue.

CONCLUSION:

The study provides evidence to support the use of capecitabine as a substitute for infusional 5FU in the management of NETs.

PMID:
21386841
[PubMed - indexed for MEDLINE]
PMCID:
PMC3068509
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Write to the Help Desk